Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073463 | 0.84 | KMT2A (0.63) | TP53TSHRMAPTHSD17B10GAA | |
| SCHEMBL14073690 | 0.79 | KMT2A (0.64) | TP53TSHRMAPTGAA | |
| SCHEMBL14073184 | 0.78 | PARP1 (0.55) | TP53POLBSMN1; SMN2PARP1TSHR | |
| SCHEMBL14073116 | 0.78 | PARP1 (0.62) | TP53PARP1TSHRMAPTMAOA | |
| SCHEMBL14073051 | 0.76 | PARP1 (0.70) | TP53PARP1TSHRMAPTMAOA | |
| SCHEMBL8198652 | 0.74 | PARP1 (0.57) | SMN1; SMN2PARP1TSHRMAPTGAA | |
| SCHEMBL14073166 | 0.74 | PARP1 (0.57) | TP53PARP1TSHRMAPTMAOA | |
| SCHEMBL14073349 | 0.73 | PARP1 (0.56) | TP53POLBPARP1TSHRMAPT | |
| SCHEMBL532518 | 0.73 | PARP1 (1.00) | TP53SMN1; SMN2PARP1TSHRMAPT | |
| SCHEMBL14073196 | 0.73 | HPGD (0.64) | POLBSMN1; SMN2PARP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | TP53 2223/4885USP2 1314/4885POLB 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.